The latest studies suggest that silencing the SCA2 gene may help reduce symptoms of ALS and deep brain stimulation may quell tics associated with Tourette’s syndrome.

Teva’s Huntington’s chorea drug names a competitive price as other drug makers pursue phase 3 studies in glioblastoma and depression despite disappointing data.

Pricing criticism strikes Roche’s Ocrevus as the nominee for FDA commissioner comes under fire for potential conflicts of interest.

The CDC says we should be paying more attention to fall-related concussion prevention in the elderly while one of the NFL’s own heads to Harvard for a neurosurgery residency.

Marathon sells off its controversial DMD drug as the FDA stands to double its fees for the drug approval process under the new Trump budget.

The Obamacare replacement is here, and opposition is growing among medical groups. Plus, alternative medicine is having its moment at some major hospitals, while telemedicine proves to be a bust for health care costs.

While Genentech rolls the dice on a second phase 3 trial for its anti-amyloid agent, a new biotech startup is tapping CRISPR technology to restore dystrophin production in Duchenne muscular dystrophy.

Follow timely coverage of the International Stroke Conference right here on Neurology Advisor.

Just days after it received FDA approval, Marathon’s Emflaza is under fire from critics who claim the price of the Duchenne muscular dystrophy drug is exorbitant.

Still feeling aftershocks from its failed Alzheimer’s trial, Eli Lilly announced more layoffs while Biogen faces an investigation into its payment programs for its top MS drugs.

Traumatic brain injury continues to make major headlines as a new crop of lawsuits hit the docket ahead of Super Bowl LI. Plus, are we too quick to rush to in-human trials? The authors of an op-ed in Nature think so.

One US town tries to take Big Pharma to court over the opioid crisis while the FDA continues to approve new, abuse-deterrent opioids. Plus, the first patient with refractory mesial temporal lobe epilepsy has undergone laser ablation surgery as part of the SLATE trial.

UCB Pharma looks to expand its epilepsy drug as Biogen cuts a deal to protect Tecfidera, while insiders suggest that pharmacists should play a bigger role in managing the growing Alzheimer’s dementia population.

The medical community questions whether mobile stroke units are sustainable, new research further links concussions with Alzheimer’s disease, and a new trial examines the effects of fasting on MS.

Happy New Year! Reflect on some of 2016’s greatest neurological advances and look forward as institutions like the NIH take on a focused effort to explore new drugs for rare disease, the developing brain, and more.

The FDA has delayed the decision on ocrelizumab after manufacturing issues arise, while it gives the thumbs up to an investigational treatment for complex regional pain syndrome.

The NCAA honored the man and ALS patient behind the viral ALS Ice Bucket Challenge, while the UK approved mitochondrial replacement reproductive assistance and Bristol-Myers Squibb faces a $20 million fine for promoting off-label uses of its antipsychotic Abilify.

The Handoff: Your Week in Neurology News – 12/8/16

While Alzheimer’s research may have hit a speed bump, research exploring gender differences in concussion and controversial treatments for autism and PTSD, including MDMA, are moving full-steam ahead.

As the neurology world awaits study results from the solanezumab trial, Boston Medical Center is investing in telehealth for epilepsy care and US prisons are administering a questionable $1,000-a-month injection for opioid addiction.

The Handoff: Your Week in Neurology News – 11/10/16

More lessons from the eteplirsen controversy, a biologic-based assessment for addiction disorders, a virtual, hassle-free trial for a potential ALS treatment, and more.

The FDA is still reeling from the Sarepta debacle, while the NFL tweaks its concussion protocol after several early-season concussions reportedly went ignored.

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news.

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news.

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news.

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news.

The Handoff is a weekly roundup of neurology news covering various developments in subspecialties, as well as pharmaceutical and association and society news.

Keep your finger on the pulse of neurology with The Handoff.

Keep your finger on the pulse of neurology with The Handoff.